. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 4b. Comparison of treatment guidelines for treatment-experienced patients infected with HCV genotype 4.

AASLD/IDSA	EASL	WHO^#	APASL
Paritaprevir/ritonavir/ombitasvir/RBV (I-A) Sofosbuvir/velapatasvir (I-A) Elbasvir/grazoprevir^d (IIa-B) Sofosbuvir/ledipasvir^a ^b (IIa-B)	PegIFN-α/RBV/sofosbuvir (B1) PegIFN-α/RBV/simeprevir, then PegIFN-α/RBV for 36 weeks (48 weeks total) (B1) Sofosbuvir/ledipasvir^a ^b (B1) Paritaprevir/ritonavir/ombitasvir/RBV (A1)^a Sofosbuvir/simepravir^a ^b (B2) Sofosbuvir/daclatasvir^a ^b (B2)	Sofosbuvir/daclatasvir^a ^b ^c Sofosbuvir/ledipasvir^a ^b ^* Alternatives Sofosbuvir/simpepravir^a ^b Paritaprevir/ritonavir/ombitasvir/RBV^a	Sofosbuvir/ledispavir^a (A1) Sofosbuvir/velpatasvir (A1)^a (B1) Paritaprevir/ritonavir/ombitasvir/dasabuvir^a (B1) Sofosbuvir/daclatasvir^a ^b (B2)

AASLD/IDSA

EASL

WHO^#

APASL

Alternatives

If the platelet count is <75 × 10³/μL, then 24 weeks of treatment with RBV should be given;

All regimens: strong recommendation, moderate quality of evidence.

24 weeks in patients with cirrhosis;

12 weeks with RBV in patients with cirrhosis;

Can be used in patients with decompensated cirrhosis;

16 weeks with RBV if prior PegIFN-α/RBV treatment failed.

Abbreviations: PegIFN, Pegylated interferon; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.